IPC’s International Fellowship program offers early-career dermatologists and researchers interested in psoriasis the opportunity to learn directly from our global network of experts, demonstrating our commitment to developing the next generation of leaders in the field.
IPC offers two fellowship tracks: Clinical and Research. Both are 12-month programs that include virtual mentoring, skills development classes, and co-mentoring groups based on special interest topics. Clinical fellows will participate in up to four weeks of on-site clinical experience, while research fellows will spend up to twelve weeks on-site with a research mentor. Applicants may apply to one or both tracks through a single application.
The project is led by the Fellowship Program Advisory Committee.
Awarded fellows are matched with IPC Board Members or Councilors to observe and participate in clinical practice or research involving patients with psoriasis. Fellows gain hands-on experience in real-world settings, whether through investigating, diagnosing, and managing psoriasis in clinical practice, or participating in active research projects in the lab or clinic. In addition, the program fosters lasting professional relationships by engaging fellows in IPC activities and connecting them with global leaders in the field throughout the fellowship year.
The 2026 IPC International Fellowship Program is supported in part by: Johnson & Johnson
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
